Syneos Health invests in Microsoft/Indegene platform

Biopharma services company Syneos Health has taken a minority stake in Indegene Omnipresence, a partnership between life sciences services company Indegene and software giant Microsoft.

The customer experience management platform includes AI and analytics elements from Microsoft, along with its business and collaboration applications, to offer CRM and omnichannel capabilities.

Manish Gupta, co-founder and CEO of Indegene, said: “We are excited to welcome Syneos Health as an investor for Indegene’s Omnipresence subsidiary. This investment will further accelerate the roadmap and deployments of our Customer Experience Management (CXM) platform for life sciences and healthcare clients. Indegene Omnipresence truly applies the power of modern omnichannel technology and advanced capabilities such as machine learning to achieve best-in-class customer-centric experiences.”

Microsoft’s corporate VP, business applications group, James Phillips said: “Omnipresence is a good example of an industry-specific, multi-cloud solution built with Microsoft’s enterprise technologies working together in uniquely disruptive ways. We are excited to see Indegene add Syneos Health as another strategic collaborator in our joint mission to bring new value to life sciences and healthcare organisations.”

The software-as-a-service (SaaS) platform was built as part of a strategic alliance that Indegene and Microsoft signed in 2017.

Following Syneos Health’s investment Sanjay Virmani, EVP with Indegene and lead of the Omnipresence initiative, will continue as the CEO of Indegene Omnipresence Inc.

Syneos Health CEO Alistair Macdonald said: “We’re excited to partner with Omnipresence the innovative platform, underpinned by Microsoft technologies, to address customer demand to drive high-value commercial relationships in an increasingly competitive marketplace.

“Syneos Health’s Dynamic Assembly network is an open ecosystem of the most agile data and technology collaborators, such as Omnipresence, to strategically address our biopharmaceutical customers’ challenges.”